ClinicalTrials.Veeva

Menu

AneuFix - Prophylactic Sac Filling

T

TripleMed

Status

Enrolling

Conditions

Endoleak
Abdominal Aortic Aneurysm

Treatments

Device: Prophylactic sac filling with AneuFix

Study type

Interventional

Funder types

Industry

Identifiers

NCT04307992
Triplemed 003

Details and patient eligibility

About

This study is set up to assess the feasibility and safety of the clinical procedure using AneuFix in a prophylactic setting at the time of EVAR endograft implantation.

Full description

The investigational device is called ANEUFIX, which is a product treating the endoleak by blockage of backflowing blood vessels, i.e. by filling the endoleak void and nidus of feeding artery and exit of existing draining arteries.

ANEUFIX is a polymer that cures rapidly (2-4 min at 37°C) after injection into the AAA-sac close to the nidus.

Enrollment

5 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Asymptomatic, infrarenal AAA that requires surgery with a high-risk profile of developing endoleak type II in line with the recommendations of Guntner et al:

    • Open IMA AND
    • 1 patent lumbar AND a cross-sectional area at the location of the IMA (CSAIMA) >17,5cm2 OR
    • 2 patent lumbars AND a CSAIMA >15cm2 OR
    • 3 patent lumbars AND a CSAIMA >12,5 cm2 OR
    • 4 patent lumbars AND a CSAIMA >10 cm2 OR
    • 5 patent lumbars AND a CSAIMA >7,5 cm2
  • Infrarenal neck according to the IFU of the EVAR device

  • Other aortic-iliac anatomical configuration suitable for EVAR according to the criteria of the EVAR device to be used

  • Patient having a life expectation of at least 2 years

  • Being older than 18 years

  • Willing and able to comply with the requirements of this clinical study

Exclusion criteria

  • Patient not able or willing to give written Informed Consent
  • Patient undergoing emergency procedures
  • Patient undergoing EVAR for ruptured or symptomatic AAA,
  • Patient with a suprarenal AAA
  • Patient with an inflammatory AAA (more than minimal wall thickening)
  • Patient with an infrarenal neck unsuitable for endovascular fixation (including so called "hostile necks") or aortic-iliac anatomic configuration otherwise unsuitable for EVAR according to criteria of the device to be used
  • Patient in which a bilateral retroperitoneal incision is required for EVAR
  • Patient in which a sacrifice of both hypogastric arteries is required
  • Patient with anatomical variations, i.e. horseshoe-kidney, arteries requiring reimplantation
  • Patient in which the administration of contrast agent is not possible: proved, severe systemic reaction to contrast agent
  • Patient with active infection present
  • Patients scheduled for or having received an organ transplant
  • Patient with limited life expectation due to other illness (<1 year)
  • Patient with non-iatrogenic bleeding diathesis
  • Patient with connective tissue disease
  • Women of child-bearing potential
  • Patients with evidence at completion angiogram during EVAR of a type Ia or type III endoleak persistent after balloon inflation

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

5 participants in 1 patient group

Intervention
Experimental group
Description:
Device: ANEUFIX
Treatment:
Device: Prophylactic sac filling with AneuFix

Trial contacts and locations

1

Loading...

Central trial contact

Tjeerd Homsma; Florie Daniels

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems